IGUSAMOD-25 TAB
MRP: 3
Packaging: 10x10
Pack Type: tablet
Composition:
Iguratimod 25mg
Indication:
for the treatment of rheumatoid arthritis (RA) to reduce joint inflammation, pain, and stiffness, and to improve physical function by suppressing inflammatory cytokines and modulating immune response.
Description:
Iguratimod 25 mg is a novel disease-modifying antirheumatic drug (DMARD) primarily used for the treatment of rheumatoid arthritis (RA) and other autoimmune joint disorders. It exhibits anti-inflammatory and immunomodulatory properties by inhibiting nuclear factor-kappa B (NF-κB) activation and suppressing the production of pro-inflammatory cytokines such as IL-6, IL-8, and TNF-α.
Unlike conventional NSAIDs, Iguratimod not only reduces inflammation but also slows disease progression, improves joint function, and preserves cartilage. It is often prescribed as a monotherapy or in combination with methotrexate in patients with inadequate response to other DMARDs.
Tags:
- Reduces inflammation and joint pain in RA
- Slows progression of joint deformities
- Immunomodulatory: suppresses cytokine production
- Better gastrointestinal tolerance compared to NSAIDs
Usage Information
Dosage
Usual dose: 25 mg orally twice daily after meals Dose adjustments: Not usually required in mild renal impairment; consult physician Do not discontinue abruptly; tapering may be necessary
Side Effects
Common: Elevated liver enzymes, nausea, diarrhea, loss of appetite Less common: Headache, rash, leukopenia Rare: Interstitial pneumonia, hepatic dysfunction, thrombocytopenia Monitoring: Periodic liver function tests and CBC are recommended
Contraindications
Hypersensitivity to Iguratimod or excipients Active infections (e.g., TB, hepatitis) Severe hepatic or renal impairment Pregnant or breastfeeding women Use with caution in the elderly and those on immunosuppressants